NYSE:BMY Bristol Myers Squibb (BMY) Stock Price, News & Analysis $62.91 +0.11 (+0.17%) Closing price 03:59 PM EasternExtended Trading$63.12 +0.22 (+0.34%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Bristol Myers Squibb Stock (NYSE:BMY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bristol Myers Squibb alerts:Sign Up Key Stats Today's Range$61.31▼$62.9650-Day Range$56.73▼$68.0652-Week Range$45.26▼$68.64Volume6.43 million shsAverage Volume10.94 million shsMarket Capitalization$128.59 billionP/E Ratio10.08Dividend Yield4.01%Price Target$65.46Consensus RatingHold Company Overview Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses. Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E. R. Squibb Company, founded in 1858. It serves patients and healthcare providers in markets around the world.AI Generated. May Contain Errors. Read More Bristol Myers Squibb Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks97th Percentile Overall ScoreBMY MarketRank™: 4.86040110106 of 5 starsBristol Myers Squibb scored higher than 97% of companies evaluated by MarketBeat, and ranked 6th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.6 / 5Analyst RatingHold Consensus RatingBristol Myers Squibb has received a consensus rating of Hold. The company's average rating score is 2.47, and is based on 2 strong buy ratings, 11 buy ratings, 16 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Bristol Myers Squibb is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageBristol Myers Squibb has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Bristol Myers Squibb's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth1.71% Earnings GrowthEarnings for Bristol Myers Squibb are expected to grow by 1.71% in the coming year, from $6.45 to $6.56 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bristol Myers Squibb is 10.08, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.24.Price to Earnings Ratio vs. SectorThe P/E ratio of Bristol Myers Squibb is 10.08, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.15.Price to Earnings Growth RatioBristol Myers Squibb has a PEG Ratio of 0.32. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioBristol Myers Squibb has a P/B Ratio of 5.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.29% of the float of Bristol Myers Squibb has been sold short.Short Interest Ratio / Days to CoverBristol Myers Squibb has a short interest ratio ("days to cover") of 4.24.Change versus previous monthShort interest in Bristol Myers Squibb has recently decreased by 6.20%, indicating that investor sentiment is improving significantly. Dividend5.0 / 5Dividend StrengthStrong Dividend LeadershipBristol Myers Squibb is a leading dividend payer. It pays a dividend yield of 4.01%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthBristol Myers Squibb has been increasing its dividend for 17 years.Dividend CoverageThe dividend payout ratio of Bristol Myers Squibb is 55.88%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Bristol Myers Squibb will have a dividend payout ratio of 38.41% next year. This indicates that Bristol Myers Squibb will be able to sustain or increase its dividend.Read more about Bristol Myers Squibb's dividend. News and Social Media4.4 / 5News Sentiment1.03 News SentimentBristol Myers Squibb has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 37 news articles for Bristol Myers Squibb this week, compared to 9 articles on an average week.Search Interest51 people have searched for BMY on MarketBeat in the last 30 days. This is an increase of 19% compared to the previous 30 days.MarketBeat Follows43 people have added Bristol Myers Squibb to their MarketBeat watchlist in the last 30 days. This is an increase of 438% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Bristol Myers Squibb insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $274,328.00 in company stock.Percentage Held by Insiders0.05% of the stock of Bristol Myers Squibb is held by insiders.Percentage Held by Institutions76.41% of the stock of Bristol Myers Squibb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bristol Myers Squibb's insider trading history. Receive BMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bristol Myers Squibb and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BMY Stock News HeadlinesEXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up HeatNovember 11 at 9:56 AM | benzinga.comActinium-225 (Ac-225) Market Size, Share, Trends, Industry Analysis, and Global Forecast to 2036 | Targeted Alpha Therapy and Capacity Expansion Drive 30.5% CAGR Toward USD 1.20 BillionNovember 10 at 1:39 PM | finance.yahoo.comURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.November 11 at 1:00 AM | Paradigm Press (Ad)Bristol-Myers Squibb: Hold Maintained as Milvexian Validation Improves, but Valuation Limits UpsideNovember 10 at 1:10 PM | tipranks.comBristol Myers Squibb (BMY) Reports 56 Week Pediatric Phase 3 Camzyos DataNovember 9 at 5:36 PM | finance.yahoo.comInsider Selling: Bristol Myers Squibb (NYSE:BMY) Director Sells 3,800 Shares of StockNovember 7, 2026 | insidertrades.comMarketBeat Week in Review – 10/26 - 10/30 (BMY)Stocks wavered after the Fed held rates steady and Alphabet's earnings missed on Search revenue, fueling AI bubble concerns despite strong results from Microsoft and resilient earnings elsewhere.October 31, 2026 | marketbeat.comBristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own StockBristol-Myers Squibb's iza-bren cut breast cancer progression risk by up to 38% in a Phase 3 trial, lifting shares and raising implications for rivals like Exelixis.October 26, 2026 | marketbeat.comSee More Headlines BMY Stock Analysis - Frequently Asked Questions How have BMY shares performed this year? Bristol Myers Squibb's stock was trading at $53.93 on January 1st, 2026. Since then, BMY shares have increased by 16.6% and is now trading at $62.9080. How were Bristol Myers Squibb's earnings last quarter? Bristol Myers Squibb Company (NYSE:BMY) issued its quarterly earnings data on Thursday, October, 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, topping the consensus estimate of $1.10 by $0.25. The company's revenue for the quarter was up 6.9% on a year-over-year basis. Read the conference call transcript. When did Bristol Myers Squibb's stock split? Shares of Bristol Myers Squibb split on the morning of Thursday, June 26th 2014.The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were payable to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. Does Bristol Myers Squibb have any subsidiaries? Bristol Myers Squibb subsidiaries include MyoKardia, Forbius, Celgene, IFM Therapeutics, Cormorant Pharmaceuticals, Padlock Therapeutics, Cardioxyl Pharmaceuticals, and others. Who are Bristol Myers Squibb's major shareholders? Top institutional investors of Bristol Myers Squibb include Pzena Investment Management LLC (0.70%), Robeco Institutional Asset Management B.V. (0.35%), Sumitomo Mitsui Trust Group Inc. (0.25%) and M&G PLC (0.22%). Insiders that own company stock include David V Elkins, Samit Hirawat, Christopher S Boerner, Theodore R Samuels II, Julia A Haller, Phil M Holzer, Benjamin Hickey and Bartie Wendy Short. View institutional ownership trends. How do I buy shares of Bristol Myers Squibb? Shares of BMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bristol Myers Squibb own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bristol Myers Squibb investors own include NVIDIA (NVDA), Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), Johnson & Johnson (JNJ), AT&T (T) and Verizon Communications (VZ). Company Calendar Record date for 11/2 Dividend10/02/2026Ex-Dividend for 11/2 Dividend10/02/2026Last Earnings10/29/2026Dividend Payable11/02/2026Today11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 4 weeks, BMY's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:BMY CIK14272 Webwww.bms.com Phone(609) 252-4621Fax212-546-4020Employees32,500Year Founded1887Price Target and Rating Average Price Target for Bristol Myers Squibb$65.46 High Price Target$78.00 Low Price Target$40.00 Potential Upside/Downside+4.1%Consensus RatingHold Rating Score (0-4)2.47 Research Coverage30 Analysts Profitability EPS (Trailing Twelve Months)$4.51 Trailing P/E Ratio10.08 Forward P/E Ratio9.59 P/E Growth0.32Net Income$7.05 billion Net Margins18.47% Pretax Margin22.65% Return on Equity60.48% Return on Assets14.45% Debt Debt-to-Equity Ratio1.79 Current Ratio1.59 Quick Ratio1.44 Sales & Book Value Annual Sales$48.19 billion Price / Sales2.67 Cash Flow$8.15 per share Price / Cash Flow7.72 Book Value$11.45 per share Price / Book5.49Miscellaneous Outstanding Shares2,044,090,000Free Float2,043,064,000Market Cap$128.59 billion OptionableOptionable Beta0.20 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NYSE:BMY) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bristol Myers Squibb Company Please log in to your account or sign up in order to add this asset to your watchlist. Share Bristol Myers Squibb With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BMY Stock Alerts